$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

[해외논문] Progrès récents dans le diagnostic, l’évaluation pronostique et le traitement des phéochromocytomes
Evolving concepts in the diagnosis, prognosis, and treatment of pheochromocytoma.

La Revue de médecine interne, v.21 no.12, 2000년, pp.1075 - 1085  

Plouin, P.F (Service d’hypertension arté) ,  Gimenez-Roqueplo, A.P (rielle, hô) ,  La Batide Alanore, A (pital europé) ,  Salenave, S (en Georges-Pompidou, 20-40, rue Leblanc, 75908 Paris cedex ) ,  Duclos, J.M (15, France)

Abstract AI-Helper 아이콘AI-Helper

AbstractIntroduction. – Pheochromocytoma is a catecholamine-secreting neoplasm of chromaffin tissue. It is a rare disease. Biochemical tests should be performed only in patients at high risk of pheochromocytoma, and an imaging procedure only in those with positive biochemical tests.Current kn...

Abstract

RésuméIntroduction. – Les phéochromocytomes sont des tumeurs sécrétant des catécholamines. Leur rareté requiert une démarche diagnostique par étapes : dépistage clinique, preuve biologique, localisation tumorale. Environ 10 % des cas sont ectopiques, 10 % familiaux, et 10 % d’évolution maligne. Les risques évolutifs dans les cas familiaux ou à risque de malignité justifient une enquête génétique, la recherche d’indicateurs pronostiques et une surveillance indéfinie.Actualités et points forts. – Le test diagnostique le plus sensible est la mesure des métanéphrines plasmatiques ou urinaires. La localisation tumorale repose sur la scanographie, l’imagerie par résonance magnétique et les scintigraphies spécifiques. Les signes phénotypiques et les preuves génomiques de l’un des trois syndromes autosomiques dominants associés au phéochromocytome doivent être recherchés dans tous les cas. Ces cas familiaux sont souvent précoces, bilatéraux et récidivants. Les phéochromocytomes peuvent être malins d’emblée ou lors d’une récidive. Les métastases sont ganglionnaires, osseuses ou viscérales. Le risque de récidive croît avec la taille de la tumeur et le débit urinaire des métanéphrines. Il est plus élevé dans les phéochromocytomes ectopiques ou ceux dont la sécrétion est immature. Ce risque justifie la surveillance clinique et biologique au moins biennale de tous les patients opérés d’un phéochromocytome.Perspectives et projets. – L’étude des mécanismes de la tumorogenèse et de l’hypersécrétion du phéochromocytome est en rapide progrès. Des progrès sont également attendus dans le traitement des cas malins : chirurgie, embolisation des métastases viscérales, plastie percutanée des métastases osseuses, radiothérapie in situ par la méta-iodobenzylguanidine iodée, traitement antisécrétoire par la métyrosine ou les analogues de la somatostatine.

주제어

참고문헌 (55)

  1. Endocr Rev Bravo 15 356 1994 10.1210/edrv-15-3-356 Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma 

  2. Hypertension Plouin 29 1133 1997 10.1161/01.HYP.29.5.1133 Tumor recurrence and hypertension persistence after successful pheochromocytoma operation 

  3. Nouv Presse Med Plouin 10 869 1981 Depistage du pheochromocytome : chez quels hypertendus ? Etude semiologique chez 2 585 hypertendus dont 11 ayant un pheochromocytome 

  4. Endocrinology Snavely 113 354 1983 10.1210/endo-113-1-354 Selective down-regulation of adrenergic receptor subtypes in tissues from rats with pheochromocytoma 

  5. Ann Intern M Heron 125 300 1996 10.7326/0003-4819-125-4-199608150-00008 The urinary metanephrine to creatinine ratio in the diagnosis of pheochromocytoma 

  6. Mayo Clin Proc St-John Sutton 56 354 1981 Prevalence of clinically unsuspected pheochromocytoma : review of a 50-year autopsy series 

  7. J Hum Hypertens Andersen 2 187 1988 The incidence rate of phaeochromocytoma and Conn’s syndrome in Denmark, 1977-1981 

  8. N Engl J M Ross 323 5 1990 Hormonal evaluation of the patient with an incidentally discovered adrenal mass 

  9. Lancet Anonymous 335 1189 1990 10.1016/0140-6736(90)92702-J Phaeochromocytoma still surprises 

  10. Does it exist ? World J Surg Proye 18 467 1994 10.1007/BF00353738 The pheochromocytoma : a benign, intra-adrenal, hypertensive, sporadic unilateral tumor 

  11. Presse Med Plouin 28 852 1999 Patients operes d’un pheochromocytome : surveillance biologique indefinie 

  12. Bull Soc Med Hop Labbe 46 982 1922 Crises solaires et hypertension paroxystique en rapport avec une tumeur surrenale 

  13. Arch Intern M 157 2413 1997 10.1001/archinte.157.21.2413 

  14. J Mal Vasc 23 204 1998 Diagnostic et traitement de l’hypertension arterielle essentielle de l’adulte de 20 a 80 ans 

  15. N Engl J M Neumann 329 1531 1993 10.1056/NEJM199311183292103 Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease 

  16. J Clin Endocrinol Metab Mulligan 80 1989 1995 10.1210/jc.80.7.1989 Genetic basis of endocrine disease : multiple endocrine neoplasia type 2 

  17. Science Latif 260 1317 1993 10.1126/science.8493574 Identification of the von Hippel-Lindau disease tumor suppressor gene 

  18. Genes Chromosomes Cancer Xu 4 337 1992 10.1002/gcc.2870040411 Loss of NF1 alleles in phaeochromocytomas from patients with type 1 neurofibromatosis 

  19. Br Med J Plouin 282 853 1981 10.1136/bmj.282.6267.853 Biochemical tests for the diagnosis of pheochromocytoma : urinary versus plasma determinations 

  20. N Engl J M Eisenhofer 340 1872 1999 10.1056/NEJM199906173402404 Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2 

  21. Radiology Quint 165 89 1987 10.1148/radiology.165.1.3628794 Phoechromocytoma and paraganglioma : comparison of MR imaging with CT and I-131 MIBG scintigraphy 

  22. Int J Urol Furuta 6 119 1999 10.1046/j.1442-2042.1999.06310.x Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy 

  23. J Nucl M Tenenbaum 36 1 1995 Comparison of radiolabeled octreotide and meta-iodobenzyl guanidine (MIBG) scintigraphy in malignant pheochromocytoma 

  24. Radiology Shulkin 212 35 1999 10.1148/radiology.212.1.r99jl3035 Pheochromocytomas : imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET 

  25. J Intern M Modigliani 238 363 1995 10.1111/j.1365-2796.1995.tb01211.x Pheochromocytoma in multiple endocrine neoplasia type 2 : European study. The Euromen Study Group 

  26. Surgery Richard 116 1076 1994 Pheochromocytoma as the first manifestation of von Hippel-Lindau disease 

  27. N Engl J M Lubs 324 1264 1991 10.1056/NEJM199105023241807 Lisch nodules in neurofibromatosis type 1 

  28. N Engl J M Eng 335 943 1996 10.1056/NEJM199609263351307 The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung’s disease 

  29. Horm Res Rodien 47 263 1997 10.1159/000185474 Genetic alterations of the RET proto-oncogene in familial and sporadic pheochromocytomas 

  30. Ann Pathol Modigliani 19 477 1999 Comment differentier un pheochromocytome sporadique d’un pheochromocytome hereditaire ? 

  31. Hum Mol Gen Crossey 3 1303 1994 10.1093/hmg/3.8.1303 Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype 

  32. J Pediatric Surg Albanese 28 1248 1993 10.1016/S0022-3468(05)80307-0 Routine bilateral adrenalectomy is not warranted in childhood familial pheochromocytoma 

  33. Surgery Lee 120 1064 1996 10.1016/S0039-6060(96)80056-0 Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma 

  34. Clin Endocrinol Shapiro 20 189 1984 10.1111/j.1365-2265.1984.tb00074.x Malignant pheochromocytoma : clinical, biochemical and scintigraphic characterization 

  35. Urology John 53 679 1999 10.1016/S0090-4295(98)00612-8 Pheochromocytomas : can malignant potential be predicted ? 

  36. Clin Endocrinol Tippett 25 401 1986 10.1111/j.1365-2265.1986.tb01706.x A reevaluation of dopamine excretion in pheochromocytoma 

  37. Plouin 917 1992 Patho-physiologic foundations of critical care The pathophysiological basis of current pheochromocytoma management 

  38. J Hypertens Plouin 6 579 1988 10.1097/00004872-198807000-00010 Plasma renin activity in pheochromocytoma : effects of betablockade and converting enzyme inhibition 

  39. Arch Mal Cœur Plouin 92 Suppl 26 1999 Facteurs associes a la morbimortalite perioperatoire chez les patients ayant un pheochromocytome benin, recidivant ou malin [abstract] 

  40. J Clin Endocrinol Metab Krempf 72 455 1991 10.1210/jcem-72-2-455 Use of m-[131I]Iodobenzylguanidine in the treatment of malignant pheochromocytoma 

  41. Br J Radiology Timmis 54 420 1981 10.1259/0007-1285-54-641-420 Therapeutic embolization of pheochromocytoma 

  42. Am J Neuroradiology Chiras 14 1113 1993 Percutaneous injection of an alcoholic embolizing emulsion as an alternative preoperative embolization for spine tumor 

  43. Ann Intern M Averbuch 109 267 1988 10.7326/0003-4819-109-4-267 Malignant pheochromocytoma : effective treatment with a combination of cyclophosphamide, vincristine and dacarbazine 

  44. Drugs Brogden 21 81 1981 10.2165/00003495-198121020-00001 Alpha-Methyl-p-tyrosine : a review of its pharmacology and clinical use 

  45. J Clin Endocrinol Metab Beldjord 80 2063 1995 10.1210/jc.80.7.2063 The RET protooncogene in sporadic pheochromocytomas : frequent MEN2-like mutations and new molecular defects 

  46. Cancer Res Le Hir 60 1365 2000 High levels of tyrosine phosphorylated proto-Ret in sporadic pheochromocytomas 

  47. J Biol Chem Kroll 274 30109 1999 10.1074/jbc.274.42.30109 von Hippel-Lindau protein induces hypoxia-regulated arrest of tyrosine hydroxylase transcript elongation in pheochromocytoma cells 

  48. Science Baysal 287 848 2000 10.1126/science.287.5454.848 Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma 

  49. J Clin Endocrinol Metab Epelbaum 80 1837 1995 10.1210/jc.80.6.1837 Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal and malignant pheochromocytomas 

  50. Endocrine Rev Lamberts 12 450 1991 10.1210/edrv-12-4-450 The role of somatostatin and its analogs in the diagnosis and treatment of tumors 

  51. Hormone Res Invitti 40 156 1993 10.1159/000183786 Effect of octreotide on catecholamine plasma levels in patients with chromaffin cell tumors 

  52. Clin Endocrinol Plouin 42 289 1995 10.1111/j.1365-2265.1995.tb01877.x Short term effects of octreotide on blood pressure and plasma catecholamines and neuropeptide Y levels in patients with pheochromocytoma : a placebo-controlled trial 

  53. Eur J Cancer Tenenbaum 32 Suppl A 737 1995 Beneficial effects of octreotide in a patient with a metastatic paraganglioma 

  54. Clin Endocrinol Kopf 46 39 1997 10.1046/j.1365-2265.1997.d01-1738.x Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant pheochromocytoma 

  55. Rev Fr Endocrinol Clin Plouin 39 129 1998 Pheochromocytomes malins : histoire naturelle et traitement 

관련 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로